Herpangina Treatment Market Report 2026

The herpangina treatment market size has grown strongly in recent years. It will grow from $1.96 billion in 2025 to $2.1 billion in 2026 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to increasing prevalence of viral infections among children, lack of targeted antiviral drugs, growth of pediatric healthcare awareness, high incidence of seasonal outbreaks, limited healthcare accessibility in rural areas.

The herpangina treatment market size is expected to see strong growth in the next few years. It will grow to $2.87 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to expansion of telehealth solutions, innovations in pain management therapies, rising homecare adoption, development of child-friendly formulations, growth in over-the-counter (OTC) medication adoption. Major trends in the forecast period include rise of pediatric telemedicine services, development of symptomatic relief formulations, increased awareness of viral infection management, adoption of homecare monitoring devices, growth in otc pain relief products.

The growing number of research and development activities is anticipated to drive the expansion of the herpangina treatment market in the coming years. Herpangina is a viral illness that primarily affects children and is characterized by painful sores or ulcers on the tonsils and the back of the throat, most commonly caused by coxsackievirus and enteroviruses. Treatments for herpangina focus on alleviating symptom severity, including blisters, high fever, throat or mouth pain, drooling, and reduced appetite. For example, in January 2024, according to the New Drug Therapy Approvals 2023 report published by the Center for Drug Evaluation and Research, a US-based branch of the U.S. Food and Drug Administration, 55 novel drugs were approved in 2023, of which 20, or 36%, were classified as first-in-class, compared with 37 novel drug approvals in 2022. As a result, the rise in research and development activity is contributing to the growth of the herpangina treatment market.

Rising healthcare expenditure is also expected to support the growth of the herpangina treatment market going forward. Healthcare expenditure includes all spending related to the provision of health services, nutrition initiatives, family planning programs, and emergency health aid. Increased healthcare spending can improve herpangina management by expanding access to trained healthcare professionals, facilities, and medical resources. For instance, in June 2025, according to the Centers for Medicare & Medicaid Services, a US-based federal agency, National Health Expenditure increased by 7.5% to $4.9 trillion in 2023, equivalent to $14,570 per person, and accounted for 17.6% of gross domestic product. Hospital expenditures grew by 10.4% to $1.51 trillion in 2023, exceeding the 3.2% growth recorded in 2022. Therefore, increasing healthcare expenditure is playing a key role in driving the growth of the herpangina treatment market.

The expanding pediatric population is further expected to fuel the growth of the herpangina treatment market in the coming years. The pediatric population includes individuals from birth through adolescence, representing the age group most commonly affected by herpangina. Treatment in pediatric patients typically emphasizes symptom relief, supportive care, and adequate hydration. For example, in December 2024, according to the Federal Interagency Forum on Child and Family Statistics, a US-based collaboration of 23 federal agencies focused on children and family research, the United States had approximately 72.5 million children in 2022, and this number is projected to increase to 78.2 million by 2050, indicating a sustained long-term growth trend. Consequently, the rising pediatric population is contributing to the continued growth of the herpangina treatment market.

Major companies operating in the herpangina treatment market are Cipla Inc., Dr. Reddys Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Zydus Cadila, Aurobindo Pharma Ltd., Lupin Limited, Glenmark Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Mucocort, Aurena Laboratories AB, CSL Limited, Bayer AG, Sanofi, Johnson & Johnson, Novartis AG, GlaxoSmithKline Plc, Boehringer Ingelheim International GmbH, Pfizer Inc, Eli Lilly and Company.

North America was the largest region in the global herpangina treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the herpangina treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the herpangina treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the herpangina treatment market by increasing the cost of imported active pharmaceutical ingredients and packaging materials, leading to higher production costs. Hospitals and specialty clinics, especially in Asia-Pacific regions such as China and India, face delays in drug supply due to import restrictions. OTC pain relief segments are particularly impacted due to reliance on global raw materials. On the positive side, tariffs have encouraged local manufacturing initiatives and innovation in domestic formulations, reducing dependency on imports.

The herpangina treatment market research report is one of a series of new reports that provides herpangina treatment market statistics, including herpangina treatment industry global market size, regional shares, competitors with a herpangina treatment market share, detailed herpangina treatment market segments, market trends and opportunities, and any further data you may need to thrive in the herpangina treatment industry. This herpangina treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Herpangina treatment refers to the management of a viral illness that commonly affects young children and causes painful sores or ulcers on the tonsils and the back of the throat. Treatment focuses on relieving symptoms and supporting the body’s natural healing process, as herpangina is a viral infection that usually resolves on its own without the need for specific antiviral medications.

The main types of herpangina treatment include topical anesthetics, ibuprofen or acetaminophen, and others. Topical anesthetics are a type of local anesthesia applied to the surface of the skin or mucous membranes to temporarily numb the affected area. Herpangina is caused by viruses such as coxsackie virus A, coxsackie virus B, enterovirus 71, and echovirus, and is associated with symptoms including high fever, sore throat, blisters or ulcers in the mouth and throat, difficulty swallowing, loss of appetite, headache, neck pain, and swollen lymph glands. These treatments are used by various end users such as hospitals, home care settings, specialty clinics, and others.

The herpangina treatment market consists of revenues earned by entities by providing medical services such as symptomatic relief, hydration, soft diet, and oral hygiene. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.